RxDoctor Payments Data

Gary Blanchard

Internal Medicine · Opelousas, LANPI 1134123706

Payments from drug & device makers

$567in general payments, 2019–2025

Across 27 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$242
  • Pfizer$75
  • Sanofi-aventis U.S. LLC$72
  • Amgen$42
  • Boehringer Ingelheim$30
  • AstraZeneca$25
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$567 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$33,601
Medicare patients
102
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$58,292
InbrijaLevodopa11$27,265
XareltoRivaroxaban30$17,861
GemtesaVibegron50$14,964
MyrbetriqMirabegron33$13,344
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,816
JanuviaSitagliptin Phosphate31$8,873
EntrestoSacubitril/Valsartan12$7,823
MovantikNaloxegol Oxalate12$5,348
CreonLipase/Protease/Amylase12$2,860
Methenamine Hippurate36$2,737
Cyclosporine12$2,631
Memantine Hcl85$2,191
Duloxetine Hcl79$2,144
Levothyroxine Sodium151$2,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$58,292130 claims
GSKTrelegy Ellipta$22$9,81614 claims
AbbVieCreon$24$2,86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →